We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksByotrol Regulatory News (BYOT)

Share Price Information for Byotrol (BYOT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.125
Bid: 0.05
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.15 (300.00%)
Open: 0.125
High: 0.125
Low: 0.125
Prev. Close: 0.125
BYOT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

State approval in US

10 May 2018 07:00

RNS Number : 5684N
Byotrol PLC
10 May 2018
 

10th May, 2018

Byotrol Plc

("Byotrol" or the "Company") 

 

APPROVAL RECEIVED FROM ALL U.S. STATES

FOR LONG-LASTING ANTI-MICROBIAL PRODUCT

 

FIRST US ORDER RECEIVED FOR ONWARD SALE ON AMAZON.COM

 

 

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that it has now completed the product registration process in the US for its 24-hour germ-kill surface sanitizer.

 

All 50 US states have now formally approved the product for sale, following receipt of approval from the US Environmental Protection Agency in June 2017.

 

The formulation has been under development at Byotrol for over 8 years and the Directors believe it offers unique performance characteristics, such as '24 hour surface protection against bacteria'. The Directors are not aware of any other EPA-approved product for US consumers that offers similar claims.

 

With the approvals in place, Byotrol is now able to sell in US retail, on-line and to institutional customers. We will be marketing our products under the name "Byotrol24"and will keep shareholders informed as we make further commercial progress.

 

We are also pleased to announce that we have already secured our first order for Byotrol24, for sale via a professional re-seller on Amazon.com. Whilst not yet meaningful in financial terms, this is a very important first step for us, not least as we have now completed the necessary registration processes for Amazon, the world's largest online shopping destination.

 

 

David Traynor, Chief Executive of Byotrol plc comments:

 

"We are now, finally, ready to go in the US. We are very excited to complete the various regulatory processes and can now move confidently on to commercialisation.

 

The order from the Amazon re-seller, whilst very small, is a key first step for us and we hope is the first in a series of positive announcements as we grow in the US."

 

 

 

Enquiries:

01925 742 000

David Traynor - Chief Executive, Byotrol plc

 

finnCap Ltd 020 7220 0500 (Nominated Adviser & Broker)

Geoff Nash/James Thompson - Corporate Finance

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

 

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens

 

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives

 

For more information, please go to www.byotrol.co.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUKVVRWUAVRAR
Date   Source Headline
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.